Holen Sie sich die Stockscreener-App
181.55
1.81%
-3.35
Handel nachbörslich:
180.27
-1.28
-0.71%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen CLO Retiring After 20 Years With Biopharma Biz - Law360
Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference - Yahoo Finance
Assessing Biogen (BIIB) Valuation After Recent Shareholder Return Momentum - simplywall.st
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders - BioSpace
Biogen’s Spinraza successor benefits SMA patients unresponsive to gene therapy - Yahoo
Swiss National Bank Cuts Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander Effective May 2026 - Minichart
Biogen Announces Upcoming Departure of Chief Legal Officer - TipRanks
Biogen chief legal officer Susan H. Alexander to depart at end of May - Investing.com
Oppenheimer reiterates Biogen stock rating on SMA drug data - Investing.com
Biogen Unveils Phase III Salanersen Program To Bring Longer-Acting SMA Option - Citeline News & Insights
Biogen builds case for Spinraza successor with fresh data - BioPharma Dive
To promote Zurzuvae, Biogen and Supernus are Turning Tides against postpartum depression - Medical Marketing and Media
Biogen Stock: Is BIIB Outperforming the Healthcare Sector? - Barchart.com
Biogen Settles Investors' $50M Claim Over Pain Drug Deal - Law360
Biogen presents additional salanersen data in SMA - The Pharma Letter
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock - Yahoo Finance
Biogen (BIIB) Reveals Promising Phase 1b Study Results for Salan - GuruFocus
Van ECK Associates Corp Has $149.46 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen presents new Phase 1b results for spinal muscular atrophy drug at MDA Conference - Traders Union
Biogen presents Phase 1b data on salanersen for SMA treatment - Investing.com
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy - Biogen
Biogen to Participate in the Stifel 2026 Virtual CNS Forum - Biogen
Therapeutics Sector Q4 2025 Earnings Review: Resilience and GrowthNews and Statistics - IndexBox
Causeway Capital Management LLC Acquires 74,163 Shares of Biogen Inc. $BIIB - MarketBeat
Jefferies Financial Group Inc. Cuts Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks - The Globe and Mail
Down 36% intraday BIIB.SW Biogen Inc. (SIX) 09 Mar 2026: catalysts to track - Meyka
MDA 2026: Trio of trials now testing Spinraza successor salanersen for SMA - SMA News Today
Rhenman & Partners Asset Management AB Boosts Biogen Stake by 358% - National Today
Rhenman & Partners Asset Management AB Has $7.70 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen’s Dravet And SMA Advances Add Depth To Long Term Story - simplywall.st
Biogen CEO touts “new era of growth” at TD Cowen as 10 Phase 3 programs near key readouts - MarketBeat
Biogen Inc (BIIB) Shares Gap Down to $181.74 on Mar 6 - GuruFocus
Health Rounds: Protein related to Parkinson's linked to faster Alzheimer's progression in women - marketscreener.com
Biogen/Stoke’s zorevunersen hailed as potential first disease-modifying drug for rare epilepsy - European Pharmaceutical Review
Spinal muscular atrophy research progresses at 2026 MDA Conference, Biogen asserts - Traders Union
What Makes Biogen (BIIB) an Attractive Long-Term Holding? - Insider Monkey
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences - Biogen
Biogen Inc Announces to Present New Data and Updates from Its Spinal Muscle Atrophy Research Programs - marketscreener.com
(BIIB) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Mo - PharmiWeb.com
Biogen (BIIB) Reports Promising Data on Zorevunersen for Dravet Syndrome - GuruFocus
Stoke Therapeutics and Biogen Announce Promising Results for Zorevunersen in Treating Dravet Syndrome, Supporting Phase 3 EMPEROR Study - Quiver Quantitative
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome - Biogen
New drug hints at changing the course of Dravet syndrome - Stock Titan
Elo Mutual Pension Insurance Co Boosts Biogen Stake - National Today
BIIB Earnings History & Surprises | EPS & Revenue Results | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Evaluating Alzheimer's Disease Treatments - Seeking Alpha
Biogen Inc. $BIIB Shares Sold by Fisher Asset Management LLC - MarketBeat
Biogen : to Participate in the Leerink Global Healthcare Conference 2026 - marketscreener.com
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Biogen to Participate in the Leerink Global Healthcare Conference 2026 - Biogen
BIIB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Mitsubishi UFJ Asset Management Boosts Biogen Holdings - National Today
Rafferty Asset Management Reduces Biogen Stake - National Today
TD Asset Management Boosts Biogen Holdings - National Today
Biogen at TD Cowen Conference: Strategic Expansion and Challenges - Investing.com India
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Biogen Inc. (BIIB) Stock Analysis: Evaluating the 7.22% Upside Potential Amidst Market Dynamics - DirectorsTalk Interviews
Biogen Deepens Its ALS Footprint With Long-Term Qalsody Safety Registry - TipRanks
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major PlayersAlnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Yahoo Finance
TD Asset Management Inc Increases Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Rafferty Asset Management LLC Lowers Stake in Biogen Inc. $BIIB - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Has $43.06 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen’s BIIB080 Readout Tests Alzheimer’s Hopes And Investor Sentiment - simplywall.st
Biogen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Biogen (BIIB) Receives a Buy from RBC Capital - The Globe and Mail
1.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):